SCHEMBL2069804

SCHEMBL2069804

Cc1nc(-c2ccc(Cl)cc2)sc1C(=O)N[C@@H]1CCCNC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 4/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
GAA P10253 1/20 0.57
PPARG P37231 1/20 0.56
PPARD Q03181 1/20 0.56
CHEK1 O14757 5/20 0.53
CDK2AP1 O14519 1/20 0.53
RAB9A P51151 2/20 0.52
KDM4E B2RXH2 1/20 0.52
NPC1 O15118 1/20 0.52
POLB P06746 1/20 0.52
PBK Q96KB5 1/20 0.52
CHRM4 P08173 1/20 0.49
MAPT P10636 2/20 0.49
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
KMT2A Q03164 1/20 0.48
BTK Q06187 1/20 0.48
GHSR Q92847 1/20 0.48
XDH P47989 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2068818 1.00 PPARA (0.59) PPARASMN1; SMN2GAAPPARGPPARD
SCHEMBL2068820 1.00 PPARA (0.59) PPARASMN1; SMN2GAAPPARGPPARD
SCHEMBL2069572 0.84 CHEK1 (0.49) PPARASMN1; SMN2GAACHEK1CDK2AP1
SCHEMBL2071887 0.83 PPARA (0.57) PPARASMN1; SMN2GAAPPARGPPARD
SCHEMBL2069694 0.80 PPARA (0.58) PPARASMN1; SMN2GAAPPARGPPARD
SCHEMBL2069652 0.79 MAPT (0.57) PPARASMN1; SMN2GAACHEK1RAB9A
SCHEMBL2069262 0.78 GAA (0.58) PPARASMN1; SMN2GAAPPARDRAB9A
SCHEMBL1564481 0.78 CHEK1 (0.67) CHEK1CDK2AP1
SCHEMBL27706276 0.77 PPARA (0.85) PPARAPPARGPPARDCHRM4
SCHEMBL12788196 0.76 SMN1; SMN2 (0.69) PPARASMN1; SMN2GAAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 US disclosed
EP-1780210-A1 NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE Kyorin Pharmaceutical Co., Ltd. (JP) 2007-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative PPARA, PPARG, PPARD PPARA 1/4885SMN1; SMN2 4185/4885GAA 3876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.